Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Teva reports strong second quarter growth

Teva reports strong second quarter growth

2nd August 2010

Teva has hailed its performance in the second quarter of 2010 after experiencing a record-breaking performance in terms of sales and growth.

The generic medicines manufacturer saw its net sales for the quarter increase to $3.8 billion (2.4 billion pounds), representing an organic growth of 12 per cent year-on-year.

All of the company’s business units posted improved figures during the three-month period, while its successful multiple sclerosis (MS) treatment Copaxone saw sales increase by 13 per cent, retaining its position as the world’s leading MS drug.

In addition, the firm has also been able to secure financing for the planned acquisition of ratiopharm, a move which will further strengthen Teva’s generics offering.

Shlomo Yanai, Teva’s president and chief executive officer, said: “This was truly a superb quarter in which Teva achieved record-breaking results, including outstanding organic growth.”

Last week, Teva announced that it will be moving to extend support of the UK pharmacy sector by offering bursaries to underprivileged students for the third consecutive year.ADNFCR-8000103-ID-800010118-ADNFCR

We have hundreds of jobs available across the Healthcare industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips and straight to your inbox.